Eric M. Yoshida

Eric M. Yoshida

Auto-generated profile, based on publicly available information

Eric M. Yoshida

Division of Gastroenterology, University of British Columbia, British Columbia, Canada

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2020 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
NDNurhan Demir
Nurhan Demir
CECumali Efe
Cumali Efe
ŞÖŞehmus Ölmez
Şehmus Ölmez
AOArzu Onur
Arzu Onur
EYEric M. Yoshida
Eric M. Yoshida
Background and Aim: Antibodies to soluble liver antigen (anti-SLA) and anti-mitochondrial autoantibodies (AMA) are two specific serological markers of autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC). They are rarely detected in the sera of patients with non-liver autoimmune disorders. Materials and Methods: The biochemical, serological, and histological findings of two celiac disease (CD) patients who were seropositive for anti-SLA and/or AMA were evaluated. Results: The data of two female patients who were 28 and 34 years old at the time of CD diagnosis were analyzed. The first patient presented with elevated liver function tests (LFTs) and immunoglobulin (Ig) G values. She was seropositive for both anti-SLA and AMA. A liver biopsy suggested features of AIH but no bile duct injury was noted. In addition to a gluten-free diet (GFD), immunosuppressive therapy was administered to normalize the LFTs. The second patient presented with elevated LFTs, a high IgG level, and a positive anti-SLA finding. A GFD was initiated, which resulted in an excellent clinical and biochemical response. Seropositivity for AMA in the first patient and anti-SLA in the second patient remained unchanged during follow-up but neither patient developed primary biliary cholangitis or AIH. Conclusion: Despite the high specificity of anti-SLA and AMA, these autoantibodies can be detected in CD without having any clinical relevance.

1 January 2026 in Hepatology Forum
Verified
Journal Article
Closed access
PDF file
KZKai Zhu
Kai Zhu
EWEric Wu
Eric Wu
BTBenson Tam
Benson Tam
EYEric M. Yoshida
Eric M. Yoshida
PKPeter Kwan
Peter Kwan
We report a case of reverse hepatitis B seroconversion in an 88-year-old woman with previously resolved hepatitis B virus (HBV) infection and sustained virologic response to hepatitis C virus (HCV) therapy. She presented with decompensated cirrhosis and was found to have newly positive hepatitis B surface antigen, hepatitis B e-antigen, and high HBV DNA levels, despite no recent immunosuppression. Entecavir was initiated with clinical and virologic improvement. This case highlights the potential for HBV reactivation years after apparent clearance, even in the absence of immunosuppression, and underscores the need for long-term monitoring in patients with prior HBV infection.